| Introduction: It has been reported that Enhancer of Zeste
Homolog 2 (EZH2) enhancer is expressed in Colorectal Cancer
(CRC), but there are only limited fndings of its overexpression
with prognosis in CRC.
Aim: To investigate the association between EZH2 expression
and clinicopathologic variables and outcome in CRC.
Materials and Methods: This retrospective study retrieved
the archived histological samples for immunohistochemistry
evaluation of EZH2 and PCR analysis of KRAS from patients with
CRC who were followed-up between April 2009 and February
2019. Kaplan-Meier methods were used for Overall Survival
(OS) and Disease-Free Survival (DFS). Cox proportional hazard
model and time dependent Cox model were used to evaluating
association of clinicopathologic factors with OS and DFS.
Results: Hundred patients with CRC were included with mean
age and range 57.39±13.52 years and 21-83 years. There were
no signifcant association between OS (log-rank p-value=0.50)
and DFS (log-rank p-value=0.74) with EZH2 expression. Third
quartile of OS was 30.7 days and for DFS was 107.83 days.
According to the result of multivariate cox regression after
adjusting for confounding variables, there was no signifcant
association between EZH2 and OS (HR =1.53, 95% CI=0.63-3.72,
p=0.35). Also, a borderline association was observed between
EZH2 and DFS (HR=11.08, 95% CI=1.02-119.72, p=0.05). There
were no signifcant associations between the DFS, OS and other
clinicopathologic parameters except for the stage, respectively
(HR=3.51, 95% CI=1.71-7.20, p=0.001) (HR=3.55, 95% CI=1.71-
7.35, p=0.001).
Conclusion: The expression of EZH2 in patients with CRC was
not associated with clinical features, and does not appear to
be associated with OS or DFS. EZH2 is an attractive target in
cancer and much more research is clearly warranted. |